Impact of estrogen type on cardiovascular safety of combined oral contraceptives
article
OA: closed
CC0
⤵ 17 in-corpus citations
AI-generated summary
This study evaluated the cardiovascular safety of combined oral contraceptives containing different types of estrogen.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ObjectivesThe International Active Surveillance study "Safety of Contraceptives: Role of Estrogens" (INAS-SCORE) investigated the cardiovascular risks associated with the use of a combined oral contraceptive (COC) containing dienogest and estradiol valerate (DNG/EV) compared to established COCs in a routine clinical setting.Study designTransatlantic, prospective, noninterventional cohort study conducted in the United States and seven European countries with two main exposure groups and one exposure subgroup: new users of DNG/EV and other COC (oCOC), particularly levonorgestrel-containing COCs (LNG). All self-reported clinical outcomes of interest (OoI) were validated via attending physicians and relevant source documents. Main OoI were serious cardiovascular events (SCE), particularly venous thromboembolic (VTEs) events. Comprehensive follow-up procedures were implemented. Statistical analyses were based on Cox regression models.ResultsA total of 50,203 new COC users were followed up for up to 5.5years (mean value, 2.1years). Overall 20.3% and 79.7% of these women used DNG/EV and oCOC (including 11.5% LNG users), respectively. A low loss to follow-up of 3.1% was achieved. Based on 47 (VTE) and 233 (SCE) events, the primary analysis (European data set) yielded adjusted hazard ratios for DNG/EV vs. oCOC of 0.4 and 0.5, respectively. The upper bounds of the 95% confidence intervals were 0.98 (VTE) and 0.96 (SCE). The corresponding hazard ratios for DNG/EV vs. LNG showed similar point estimates but the confidence intervals included unity.ConclusionDNG/EV is associated with similar or even lower cardiovascular risk compared to oCOC and LNG.Implication statementA COC containing DNG and EV is associated with similar or even lower cardiovascular risk compared to COCs containing levonorgestrel or other progestogens.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (26)
- Effect of four oral contraceptives on hemostatic parameters via openalex
- Efficacy and Safety of a Combined Oral Contraceptive Containing Estradiol Valerate/Dienogest: Results from a Clinical Study Conducted in North America via openalex
- The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval via openalex
- doi:10.1177/0141076814562718 via openalex
- doi:10.1783/147118908786000596 via openalex
- doi:10.1002/tera.1420460110 via openalex
- W6634173072 via openalex
- W6638294336 via openalex
- W6638474973 via openalex
- doi:10.1126/science.7618077 via openalex
- doi:10.1783/147118908784734873 via openalex
- doi:10.1001/archinternmed.2008.589 via openalex
- doi:10.1001/archinte.163.22.2759 via openalex
- doi:10.1177/003591576505800503 via openalex
- doi:10.1097/aog.0b013e3182a5ec6b via openalex
- doi:10.1016/j.contraception.2016.01.012 via openalex
- doi:10.1093/oxfordjournals.aje.a115939 via openalex
- doi:10.3109/13625187.2015.1005445 via openalex
- doi:10.1016/j.contraception.2014.01.023 via openalex
- doi:10.1016/s0140-6736(00)04645-6 via openalex
- doi:10.1515/pubhef-2005-2191 via openalex
- doi:10.1093/ije/17.4.955 via openalex
- doi:10.1093/oxfordjournals.aje.a010135 via openalex
- doi:10.1177/000331970105200601 via openalex
- doi:10.1016/j.contraception.2006.12.019 via openalex
- W1826890184 via openalex
Cited by (12)
- Venous Thromboembolic Risk of Estradiol Valerate–Dienogest Compared with Ethinyl Estradiol–Levonorgestrel Combined Oral Contraceptives 2024
- Estradiol Valerate vs Ethinylestradiol in Combined Oral Contraceptives: Effects on the Pituitary-Ovarian Axis 2022
- Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview 2022
- Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies 2021
- Real world data on symptomology and diagnostic approaches of 27,840 women living with endometriosis 2021
- THERAPY OF COPIOUS MENSTRUAL BLEEDING IN A FEMALE PATIENT OF REPRODUCTIVE AGE 2021
- Patient-reported utilization patterns of endometriosis medications in Europe: Real-world results from the non-interventional VIPOS study 2021
- Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under 2020
- Overview of the therapeutic possibilities of combined oral contraceptive containing estradiol valerate and dienogest 2019
- Hormone Replacement Therapy in Premature Ovarian Insufficiency 2019
- Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis 2017
- Contraception for the perimenopausal woman 2016
Source provenance
- openalex
- last seen: 2026-05-11T05:40:41.230350+00:00
- unpaywall
- last seen: 2026-08-19T06:23:00.919175+00:00
License: CC0
· commercial use OK